Profile: Seattle Genetics Inc (SGEN.O)
7 Mar 2014
Seattle Genetics, Inc., incorporated on July 15, 1997, is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma (s ALCL), after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology.
It has collaboration agreement with Takeda Oncology Company to develop and commercialize ADCETRIS. It also have collaborations for our ADC technology with a number of biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd. (formerly part of Abbott Laboratories), (AbbVie); Bayer Pharmaceuticals Corporation, (Bayer); Celldex Therapeutics, Inc., (Celldex); Daiichi Sankyo Co., Ltd., (Daiichi Sankyo); Genentech, Inc., a member of the Roche Group, (Genentech); GlaxoSmithKline LLC, or (GSK); Millennium, Pfizer, Inc., (Pfizer), and PSMA Development Company LLC, a subsidiary of Progenics Pharmaceuticals Inc., (Progenics); as well as ADC co-development agreements with Agensys, Inc., an affiliate of Astellas Pharma, Inc., (Agensys, Genmab A/S) and Oxford BioTherapeutics Ltd., or (OBT).
The Company’s pipeline of monoclonal antibody-based product candidates is based on its ADC technology. ADCs are monoclonal antibodies that are linked to cytotoxic or cell-killing agents. Its ADCs utilize monoclonal antibodies, which internalize within target cells after binding to their cell-surface receptors. Enzymes present inside the cell catalyze the release of the cytotoxic agent from the monoclonal antibody, which then results in the desired activity, specific killing of the target cell.
ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. ADCETRIS employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells. ADCETRIS was granted approval in two indications under the FDA’s accelerated approval regulations, which allows the FDA to approve products for cancer or other serious or life-threatening illnesses based on data surrogate endpoints or on a clinical endpoint other than survival or irreversible morbidity.
SGN-75 is an ADC composed of an anti-CD70 monoclonal antibody linked to a potent auristatin compound using its ADC technology. In November 2009, the Company initiated a single-agent phase I study of SGN-75 for patients with CD70-expressing relapsed or refractory renal cell carcinoma or non-Hodgkin lymphoma. This trial was designed to enroll up to 80 patients at multiple centers in the United States to evaluate the safety, tolerability, pharmacokinetic profile and antitumor activity of SGN-75.
ASG-5ME is an ADC composed of an anti-SLC44A4 monoclonal antibody linked to a potent auristatin compound using its ADC technology. SLC44A4 is a target expressed on more than 80% of pancreatic, prostate and gastric cancer tumors and is also expressed in more than 50% of breast cancer tumors, based on preclinical data. The Company is developing ASG-5ME as a product candidate for the treatment of solid tumors under its co-development collaboration with Agensys.
ASG-22ME is an ADC composed of an anti-Nectin-4 monoclonal antibody linked to a potent auristatin compound using its ADC technology. Nectin-4 is a target expressed in multiple cancers including bladder, breast, lung and pancreatic cancers. the Company is developing ASG-22ME as a product candidate for the treatment of solid tumors under its co-development collaboration with Agensys.
SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody linked to a potent auristatin compound using its ADC technology, and is a product candidate for the treatment of hematologic malignancies. CD19 is a B-cell antigen that is expressed in non-Hodgkin lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia. The Company has previously reported preclinical data demonstrating that SGN-CD19A binds to target cells with high affinity, internalizes and induces potent cancer-cell-killing activity and durable tumor regressions at low doses in multiple cancer models.
The Company competes with Amgen, Aventis, Bayer, Biogen IDEC, Bristol-Myers Squibb, Celgene, Eisai, Genentech, GSK, Gilead, ImmunoGen, Infinity, Merck, Millennium, Novartis, Pfizer, Pharmacyclics, Sanofi-Aventis, Spectrum Pharmaceuticals, and Teva
Seattle Genetics Inc
21823 30TH DRIVE SE
BOTHELL WA 98021